In today’s briefing:
- GAPack (468 HK): Unpacking XJF’s Move To Send The Board Packing
- 2024 High Conviction: Meituan / MT (3690 HK) – Big Opportunity Emerging After Plunge
- Pinduoduo (PDD US): TEMU at Center Stage
- [Futu Holdings(FUTU US, SELL, TP US$46)Rating Change]: Run Out of Growth Momentum, Downgrade to SELL
- Sunho Biologics (盛禾) Pre-IPO: Testing the Unproven Targets
- Morning Views Asia: Azure Power Global Ltd, Powerlong Commercial Management Holdings
GAPack (468 HK): Unpacking XJF’s Move To Send The Board Packing
- Back on the 27 January 2023, Jardine Matheson (JM SP) entered an agreement with Shandong Xinjufeng (301296 CH) (XJF) to sell its 28.22% stake in GAPack (468 HK).
- That sale completed in September. Last week, XJF requisitioned an EGM to consider appointing five new (& friendly) directors, all-but taking control of the board.
- CEO and founder Jeff Bi holds 9.65%. The question is: what are his options?
2024 High Conviction: Meituan / MT (3690 HK) – Big Opportunity Emerging After Plunge
- The stock has been declining for about three years and plummeted after the 3Q23 results.
- However, we believe MT and its corporate clients have been recovering and MT’s profits will rise by 129% in 2024.
- We set an upside of 132% and a price target of HK$209 for 2024. Buy.
Pinduoduo (PDD US): TEMU at Center Stage
- Stock rally on strong revenue growth suggests TEMU will be at center stage of the investment thesis for PDD down the road.
- Besides soaring GMV, TEMU achieved blowout performance likely due to much higher-than-expected take-rate and disciplined marketing, resulting in narrower-than-expected losses.
- We expect the company’s growth will even accelerate in 4Q23 and generate adjusted net profit of US$12 bn for FY24, with a target market cap of US$240 bn (20xPE).
[Futu Holdings(FUTU US, SELL, TP US$46)Rating Change]: Run Out of Growth Momentum, Downgrade to SELL
- We think FUTU is stepping into a stagnant phase in 2024. Japan is not a game changer.
- Client asset inflow from overseas is not meaningful, and growth from mainland is frozen by regulation.
- We downgrade the stock into SELL rating and cut TP to US$46/ADS, mainly due to slow progress in overseas expansion and difficulty in monetization.
Sunho Biologics (盛禾) Pre-IPO: Testing the Unproven Targets
- Sunho Biologics, a China-based clinical-stage biotechnology company, plans to raise up to US$100m via a Hong Kong listing.
- In this note, we examine the company’s three core products, namely IAP0971, IAE0972, and IAH0968, which target malignancies.
- A large part of the company’s pipeline is testing the unproven targets. We also think the management and pre-IPO investors are of mediocre quality.
Morning Views Asia: Azure Power Global Ltd, Powerlong Commercial Management Holdings
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.